Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
- Conditions
- HyponatremiaInappropriate ADH Syndrome
- Interventions
- Drug: placebo
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2
- Registration Number
- NCT00728091
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1229
- Registration Number
- NCT00726674
- Locations
- 🇮🇱
Sanofi-Aventis Administrative Office, Natanya, Israel
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
- Conditions
- Abdominal Neoplasms
- Interventions
- Other: Physical prophylaxis
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2010-04-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 151
- Registration Number
- NCT00723216
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer
- Conditions
- Therapy, Prostatic Neoplasms
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT00723086
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1003
- Registration Number
- NCT00721760
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 826
- Registration Number
- NCT00718965
- Locations
- 🇵🇷
Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico
AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2013-03-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 71
- Registration Number
- NCT00719524
- Locations
- 🇫🇷
Investigational Site Number 250001, Villejuif, France
🇨🇭Investigational Site Number 756001, Bellinzona, Switzerland
🇮🇹Investigational Site Number 380001, Milano, Italy
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1150
- Registration Number
- NCT00718224
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
CASTLE (Clopidogrel And Serum Troponin Level Elevation)
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2009-09-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 155
- Registration Number
- NCT00716924
- Locations
- 🇲🇽
Sanofi aventis administrative office, Mexico, Mexico
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: PlaceboDevice: Pen auto-injector
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 496
- Registration Number
- NCT00715624
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom